Singapore markets close in 3 hours 46 minutes

ABBV Jan 2024 135.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
14.100.00 (0.00%)
As of 12:57PM EDT. Market open.
Full screen
Loading interactive chart…
  • Motley Fool

    Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

    With the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green lights from regulators, it isn't too surprising why. Most recently, on Sept. 10, it announced that a pair of its phase 3 trials of Skyrizi, a psoriatic arthritis drug that's already on the market, showed that the drug was performing favorably in long-term followup studies.

  • Motley Fool

    Here's Why This Dividend King Is a Buy

    Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.

  • Motley Fool

    Where Will AbbVie Be in 3 Years?

    In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.